Ryvu Therapeutics (STU:9Y4) Total Operating Expense: €29.58 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9Y4 Ryvu Therapeutics SA STU:9Y4
68 GF Score
Price €3.31
GF Value €10.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Total Operating Expense?

Ryvu Therapeutics STU:9Y4 -0.45% 68 Total Operating Expense is €29.58 Mil as of Mar. 2026. GuruFocus rates STU:9Y4 with a GF Score™ of 68/100 and a GF Value™ of €10.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

Ryvu Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was €5.79 Mil. Ryvu Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €29.58 Mil.

Ryvu Therapeutics Total Operating Expense Related Terms

Ryvu Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Ryvu Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ryvu Therapeutics Total Operating Expense Chart

Ryvu Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.67 20.89 29.07 41.38 33.19

Ryvu Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.40 8.32 8.42 7.05 5.79
STU:9Y4
68GF Score
Ryvu Therapeutics SA STU:9Y4
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ryvu Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €29.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €29.58 Mil mean?
Ryvu Therapeutics (STU:9Y4) has a Total Operating Expense of €29.58 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Total Operating Expense too high?
Ryvu Therapeutics' current Total Operating Expense is €29.58 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Total Operating Expense compare to VRTX and REGN?
Ryvu Therapeutics' Total Operating Expense of €29.58 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Total Operating Expense is €29.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (STU:9Y4) is currently considered Possible Value Trap. The stock's GF Value™ is €10.19, compared to a current price of €3.31 — trading 67.6% below its estimated fair value. The current Total Operating Expense is €29.58 Mil. Ryvu Therapeutics' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Ryvu Therapeutics (STU:9Y4), the current Total Operating Expense is €29.58 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ryvu Therapeutics (STU:9Y4) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of €3.31 is trading 67.6% below its estimated GF Value™ of €10.19. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for STU:9Y4:

  • Total Operating Expense: €29.58 Mil
  • GF Value™: €10.19 vs. price of €3.31 (67.6% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the STU:9Y4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges RVU:Poland
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
68GF Score

Get the complete analysis for STU:9Y4

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.31
Price
€10.19
GF Value